Why is Cooper Companies stock plunging 15% today?
Cooper Companies (COO) stock fell 15.3% to $53.76 in pre-market trading after reporting fiscal Q3 2026 revenue of $1.07B, missing estimates by $30M. Adjusted EPS of $1.15 beat expectations. The company cut Q4 guidance, citing inventory reduction headwinds. The board decided to retain CooperSurgical after a strategic review. Piper Sandler and Baird downgraded the stock, citing weak growth and margin prospects.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut led to immediate analyst downgrades and a sharp pre‑market sell‑off, outweighing positive cash flow and buyback news.
Market read
The earnings surprise and guidance cut are the primary drivers of a 15% pre‑market decline, making the news highly relevant for traders.
What to watch
Record free cash flow and expanded buyback program could provide a floor for the stock if guidance improves.
Background
Cooper Companies' Q3 earnings were released after market close, with revenue slightly below estimates and a notable guidance reduction for Q4.
Ticker impact
Cooper Companies reported Q3 revenue miss and cut Q4 guidance, triggering a 15% pre‑market stock plunge.
Further downside expected as investors reassess growth prospects.
Guidance cut below consensus and analyst downgrades signal weaker near‑term performance.
Market effects
Vision care and surgical device sectors may see broader pressure as peers face similar growth concerns.
U.S. markets see limited offsetting support; broader indices edge higher despite the drop.
Limited to investors tracking U.S. med‑tech stocks.
Counterpoint
Buy‑the‑dip traders may view the price drop as an overreaction given strong free cash flow and share repurchase expansion.
Key entities
- CompanyCooper Companies
Medical device manufacturer (ticker COO).
- AnalystPiper Sandler
Downgraded COO to Neutral and cut price target.
- AnalystBaird
Downgraded COO to Neutral and cut price target.
